| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by first author.
Page 8: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 2101 | 9 | 34 | 1142 1994 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 16(4):717-729 SHANNON EJ; HOWE RC; MCLEAN K; HASTINGS RC THALIDOMIDE DOES NOT PERTURB CD2, CD4, CD5, CD8, HLA-DR, OR HLA-A, HLA-B, HLA-C MOLECULES IN-VITRO ON THE MEMBRANES OF CELLS WITH IMMUNE POTENTIAL | 5 | 5 |
| 2102 | 0 | 0 | 671 1978 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 46(1):121-121 SHANNON EJ; MIRANDA RO; HASTINGS RC INHIBITION OF DENOVO ANTIBODY-SYNTHESIS BY THALIDOMIDE | 0 | 0 |
| 2103 | 0 | 0 | 700 1979 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 47(2):381-382 SHANNON EJ; MIRANDA RO; HASTINGS RC EFFECT OF THALIDOMIDE ON DENOVO ANTIBODY-SYNTHESIS | 3 | 3 |
| 2104 | 4 | 36 | 765 1981 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 13(6):553-562 SHANNON EJ; MIRANDA RO; MORALES MJ; HASTINGS RC INHIBITION OF DENOVO IGM ANTIBODY-SYNTHESIS BY THALIDOMIDE AS A RELEVANT MECHANISM OF ACTION IN LEPROSY | 32 | 41 |
| 2105 | 12 | 22 | 1339 1997 IMMUNOPHARMACOLOGY 35(3):203-212 Shannon EJ; Morales MJ; Sandoval F Immunomodulatory assays to study structure-activity relationships of thalidomide | 10 | 13 |
| 2106 | 10 | 25 | 1199 1995 IMMUNOPHARMACOLOGY 31(1):109-116 SHANNON EJ; SANDOVAL F THALIDOMIDE INCREASES THE SYNTHESIS OF IL-2 IN CULTURES OF HUMAN MONONUCLEAR-CELLS STIMULATED WITH CONCANAVALIN-A, STAPHYLOCOCCAL-ENTEROTOXIN-A, AND PURIFIED PROTEIN DERIVATIVE | 34 | 37 |
| 2107 | 4 | 22 | 1268 1996 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 18(1):59-72 Shannon EJ; Sandoval F Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells | 21 | 24 |
| 2108 | 0 | 0 | 1262 1996 FASEB JOURNAL 10(6):303-303 Shannon EJ; Sandoval F; Krahenbuhl J Hydrolysis of thalidomide abrogates its ability to enhance IL-2 or to suppress TNF-alpha. | 0 | 0 |
| 2109 | 12 | 21 | 1340 1997 IMMUNOPHARMACOLOGY 36(1):9-15 Shannon EJ; Sandoval F; Krahenbuhl JL Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha | 17 | 18 |
| 2110 | 11 | 22 | 2204 2002 INTERNATIONAL IMMUNOPHARMACOLOGY 2(8):1143-1153 Shannon EJ; Sandoval FG Thalidomide can costimulate or suppress CD4(+) cells' ability to incorporate [H-3]-thymidine-dependence on the primary stimulant | 4 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2111 | 6 | 13 | 902 1985 LEPROSY REVIEW 56(4):297-301 SHANNON EJ; TRUMAN RW; CHRISTY SA; BROWN LM; VADIEE R; HASTINGS RC EFFECT OF THALIDOMIDE ON INDUCTION OF ANTIBODY-SYNTHESIS IN MICE TO THE T-INDEPENDENT ANTIGEN, DNP-FICOLL | 5 | 6 |
| 2112 | 0 | 0 | 889 1985 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 53(1):165-166 SHANNON EJ; TRUMAN RW; CHRISTY SA; VADIEE R; HASTINGS RC EFFECT OF THALIDOMIDE ON INDUCTION OF ANTIBODY-SYNTHESIS IN MICE TO A T-INDEPENDENT ANTIGEN - DNP FICOLL | 0 | 0 |
| 2113 | 4 | 4 | 1354 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 15(5):392-392 Sharp M; Getty J; Klausner JD Thalidomide use is associated with weight gain in HIV-1-positive clients | 2 | 2 |
| 2114 | 11 | 39 | 1338 1997 GASTROENTEROLOGY 112(6):1823-1829 Sharpstone D; Rowbottom A; Francis N; Tovey G; Ellis D; Barrett M; Gazzard B Thalidomide: A novel therapy for microsporidiosis | 12 | 42 |
| 2115 | 1 | 5 | 1166 1995 AIDS 9(6):658-659 SHARPSTONE D; ROWBOTTOM A; NELSON M; GAZZARD B THE TREATMENT OF MICROSPORIDIAL DIARRHEA WITH THALIDOMIDE | 14 | 34 |
| 2116 | 0 | 0 | 1673 2000 BLOOD 96(11):579A-+ Shaughnessy J; Zhan F; Tian E; Bumm K; Muller G; Stirling D; Tricot G; Barlogie B Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD. | 0 | 2 |
| 2117 | 4 | 12 | 327 1965 CHEMISTRY & INDUSTRY (24):1030-& SHEALY YF; OPLIGER CE; MONTGOME.JA D-AND 6-THALIDOMIDE | 0 | 16 |
| 2118 | 9 | 66 | 465 1968 JOURNAL OF PHARMACEUTICAL SCIENCES 57(5):757-& SHEALY YF; OPLIGER CE; MONTGOME.JA SYNTHESIS OF D-AND L-THALIDOMIDE AND RELATED STUDIES | 12 | 29 |
| 2119 | 8 | 8 | 913 1986 ARTHRITIS AND RHEUMATISM 29(10):1296-1296 SHEEHAN NJ THALIDOMIDE NEUROTOXICITY AND RHEUMATOID-ARTHRITIS | 2 | 2 |
| 2120 | 10 | 22 | 1595 1999 PEDIATRICS 103(6):1295-1297 Shek LPC; Lee YS; Lee BW; Lehman TJA Thalidomide responsiveness in an infant with Behcet's syndrome | 10 | 16 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2121 | 19 | 48 | 2046 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):31-35 Shek LPC; Lim DLC Thalidomide in Behcet's disease | 7 | 10 |
| 2122 | 0 | 0 | 792 1982 TERATOLOGY 25(2):A75-A75 SHEPARD TH; SHIOTA K BIOACTIVATION OF THALIDOMIDE BY A MONKEY LIVER FRACTION IN A RAT LIMB CULTURE SYSTEM | 0 | 0 |
| 2123 | 0 | 1 | 581 1973 SOCIAL SCIENCE & MEDICINE 7(2):161-162 SHEPHERD J ABNORMALITY AND NORMALITY - MOTHERING OF THALIDOMIDE CHILDREN - ROSKIES,E | 0 | 0 |
| 2124 | 8 | 28 | 922 1986 FOOD AND DRUG LAW JOURNAL 41(4):458-466 SHERMAN M; STRAUSS S THALIDOMIDE - A 25-YEAR PERSPECTIVE | 4 | 14 |
| 2125 | 0 | 0 | 330 1965 CLINICAL PHARMACOLOGY & THERAPEUTICS 6(3):303-& SHESKIN J THALIDOMIDE IN TREATMENT OF LEPRA REACTIONS | 215 | 259 |
| 2126 | 0 | 344 1965 LEPROSY REVIEW 36:183-187 SHESKIN J Further observations with thalidomide in lepra reactions | 38 | 52 | |
| 2127 | 4 | 19 | 612 1975 HAUTARZT 26(1):1-5 SHESKIN J THERAPEUTIC EFFECTS OF THALIDOMIDE IN LEPROSY REACTION | 22 | 25 |
| 2128 | 0 | 0 | 613 1975 HAUTARZT 26(4):215-215 SHESKIN J THERAPY OF PRURIGO NODULARIS HYDE WITH THALIDOMIDE | 28 | 30 |
| 2129 | 0 | 0 | 669 1978 INTERNATIONAL JOURNAL OF DERMATOLOGY 17(1):82-84 SHESKIN J STUDY WITH NINE THALIDOMIDE DERIVATIVES IN LEPRA REACTION | 3 | 8 |
| 2130 | 0 | 0 | 703 1979 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 47(2):433-433 SHESKIN J TREATMENT OF LEPROMATOUS-LEPRA REACTION, WITH SPECIAL REFERENCE TO THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2131 | 7 | 67 | 727 1980 INTERNATIONAL JOURNAL OF DERMATOLOGY 19(6):318-322 SHESKIN J THE TREATMENT OF LEPRA REACTION IN LEPROMATOUS LEPROSY - 15 YEARS EXPERIENCE WITH THALIDOMIDE | 45 | 57 |
| 2132 | 0 | 0 | 753 1981 INTERNATIONAL JOURNAL OF DERMATOLOGY 20(3):220-220 SHESKIN J THALIDOMIDE - REPLY | 0 | 0 |
| 2133 | 1 | 7 | 748 1981 DERMATOLOGICA 163(2):145-150 SHESKIN J; GORODETSKY R; WEINREB A; LOEWINGER E IRON CONTENT OF SKIN BEFORE AND AFTER THALIDOMIDE TREATMENT OF LEPRA REACTION - A PRELIMINARY-REPORT | 0 | 5 |
| 2134 | 1 | 5 | 747 1981 DERMATOLOGICA 162(2):86-90 SHESKIN J; GORODETZKY R; LOEWINGER E; WEINREB A INVIVO MEASUREMENTS OF IRON, COPPER AND ZINC IN THE SKIN OF PRURIGO NODULARIS PATIENTS TREATED WITH THALIDOMIDE | 3 | 11 |
| 2135 | 5 | 14 | 822 1983 HAUTARZT 34(4):168-170 SHESKIN J; MUCKTER H; FRANKUS E SUPIDIMIDE, A NON-TERATOGENIC ANALOG OF THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS | 2 | 2 |
| 2136 | 0 | 0 | 496 1970 ARCHIV FUR KLINISCHE UND EXPERIMENTELLE DERMATOLOGIE 237(1):312-& SHESKIN J; SAGHER F CURRENT STATUS OF THALIDOMIDE TREATMENT OF LEPROSY AND LEPRA REACTIONS | 2 | 5 |
| 2137 | 3 | 15 | 462 1968 ISRAEL JOURNAL OF MEDICAL SCIENCES 4(4):901-& SHESKIN J; SAGHER F; DORFMAN M; VONSCHRA.HW UNSATISFACTORY RESULTS WITH THALIDOMIDE AS A SPECIFIC TREATMENT FOR LEPROSY | 13 | 13 |
| 2138 | 3 | 9 | 697 1979 HAUTARZT 30(7):376-379 SHESKIN J; YAAR I MOTOR CONDUCTIVITY OF CUBITAL NERVES IN PATIENTS WITH LEPRA REACTION - EXPERIENCE OF 13 YEARS DURING THALIDOMIDE-TREATMENT | 15 | 17 |
| 2139 | 0 | 0 | 2079 2002 BLOOD 100(11):337B-337B Shetty V; Alvi S; Zorat F; Patkar S; Zahid S; Khan T; Mundle S; Galili N; Reddy P; Alvi M; Lisak L; Gezer S Effect of the anti-angiogenic agent thalidomide on the biological characteristics of patients with myelodysplastic syndromes. | 0 | 0 |
| 2140 | 0 | 0 | 1798 2001 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U653-U653 Shi JD; Xiao ZL; Marks M; Kamat C; Pokala V Development of thalidomide analogs as anti-angiogenic agents. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2141 | 0 | 0 | 1502 1999 BLOOD 94(10):125A-125A Shima Y; Treon SP; Yoshizaki K; Tai YT; Hideshima T; Raje N; Chauhan D; Davies F; Schlossman R; Anderson KC Clinical and biological activity of thalidomide (Thal) in multiple myeloma (MM). | 0 | 11 |
| 2142 | 8 | 26 | 1498 1999 BIOLOGICAL & PHARMACEUTICAL BULLETIN 22(2):224-226 Shimazawa R; Miyachi H; Takayama H; Kuroda K; Kato F; Kato M; Hashimoto Y Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide | 10 | 16 |
| 2143 | 6 | 23 | 2608 2004 CHEMICAL & PHARMACEUTICAL BULLETIN 52(4):498-499 Shimazawa R; Sano H; Tanatani A; Miyachi H; Hashimoto Y Thalidomide as a nitric oxide synthase inhibitor and its structural development | 1 | 1 |
| 2144 | 6 | 23 | 1572 1999 JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN 57(2):92-104 Shimazawa R; Takayama H; Hashimoto Y Development of novel biological response modifiers derived from thalidomide | 0 | 7 |
| 2145 | 0 | 16 | 1034 1990 TOXICOLOGY LETTERS 50(2-3):309-318 SHIOTA K; UWABE C; YAMAMOTO M; ARISHIMA K SUSCEPTIBILITY TO CYCLOPHOSPHAMIDE AND THALIDOMIDE OF FETAL-RAT LIMB BUDS GRAFTED IN ATHYMIC (NUDE) MICE | 0 | 0 |
| 2146 | 11 | 15 | 257 1963 PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE 113(3):619-& SHORB MS; POLLARD W; VASAITIS V; LUND PG; SMITH C EFFECT OF THALIDOMIDE TREATMENT OF HENS ON EMBRYONIC DEVELOPMENT AND FERTILITY | 3 | 7 |
| 2147 | 9 | 23 | 1966 2001 JOURNAL OF NEURO-ONCOLOGY 51(1):41-45 Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M Thalidomide as an anti-angiogenic agent in relapsed gliomas | 10 | 20 |
| 2148 | 9 | 144 | 856 1984 JOURNAL OF THEORETICAL BIOLOGY 110(3):461-486 SHULL GE DIFFERENTIAL INHIBITION OF PROTEIN-SYNTHESIS - A POSSIBLE BIOCHEMICAL-MECHANISM OF THALIDOMIDE TERATOGENESIS | 4 | 6 |
| 2149 | 1 | 6 | 2300 2003 AMERICAN JOURNAL OF GASTROENTEROLOGY 98(1):221-222 Shurafa M; Kamboj G Thalidomide for the treatment of bleeding angiodysplasias | 1 | 2 |
| 2150 | 1 | 9 | 2144 2002 BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1315-1316 Shuttleworth GN; Cook SD; Ropner JE Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2151 | 0 | 0 | 2098 2002 BLOOD 100(11):390B-390B Sidra GM; Russell N; Byrne J; Myers B; Mitchell D Combination therapy with thalidomide, cyclophosphamide and dexamethasone (C-ThaD) for VAD-refractory and relapsed myeloma. | 0 | 0 |
| 2152 | 7 | 32 | 1568 1999 JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 15(5):429-438 Siefert B; Pleyer U; Muller M; Hartmann C; Keipert S Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide | 0 | 10 |
| 2153 | 0 | 0 | 212 1963 COLUMBIA JOURNALISM REVIEW 1(4):53-53 SILBER F MORE ON THALIDOMIDE | 0 | 0 |
| 2154 | 3 | 23 | 1155 1994 NEPHRON 67(3):270-273 SILVA SRB; VIANA PCF; LUGON NV; HOETTE M; RUZANY F; LUGON JR THALIDOMIDE FOR THE TREATMENT OF UREMIC PRURITUS - A CROSSOVER RANDOMIZED DOUBLE-BLIND TRIAL | 20 | 43 |
| 2155 | 15 | 44 | 2665 2004 MAYO CLINIC PROCEEDINGS 79(7):857-858 Silver RT Myelofibrosis: Thalidomide finds a new disease | 0 | 0 |
| 2156 | 1 | 8 | 482 1969 DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY 11(6):743-& SIMARD TG; LADD HW CONSCIOUS CONTROL OF MOTOR UNITS WITH THALIDOMIDE CHILDREN - AN ELECTROMYOGRAPHIC STUDY | 0 | 4 |
| 2157 | 10 | 12 | 1310 1997 ANALYTICA CHIMICA ACTA 339(1-2):91-97 Simmons BR; Lush RM; Figg WD A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum | 8 | 10 |
| 2158 | 0 | 1 | 551 1972 HEALTH EDUCATION JOURNAL 31(1):130-130 SIMPSON EE STUDIES IN CHILD DEVELOPMENT - CHALLENGE OF THALIDOMIDE - PRINGLE,MLK AND FIDDES,DO | 0 | 0 |
| 2159 | 0 | 1 | 17 1961 BRITISH MEDICAL JOURNAL 2(NOV11):1287-& SIMPSON JA NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 4 | 7 |
| 2160 | 1 | 2 | 55 1962 BRITISH MEDICAL JOURNAL (5270):55-& SIMPSON JA MYXOEDEMA AFTER THALIDOMIDE (DISTAVAL) | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2161 | 1 | 3 | 200 1963 BRITISH MEDICAL JOURNAL (537):1527-& SIMPSON JA THALIDOMIDE NEUROPATHY | 0 | 0 |
| 2162 | 1 | 2 | 429 1967 CURRENT SCIENCE 36(20):556-& SINGH D; JOSHI BC CHROMOSOME BREAKAGE INDUCED BY HYDROLYTIC PRODUCTS OF THALIDOMIDE IN VICIA FABA | 0 | 0 |
| 2163 | 1 | 1 | 1766 2000 NEW ENGLAND JOURNAL OF MEDICINE 342(5):364-364 Singhal S Antitumor activity of thalidomide in refractory multiple myeloma (vol 341, pg 1565, 1999) | 7 | 15 |
| 2164 | 52 | 73 | 1822 2001 BIODRUGS 15(3):163-172 Singhal S; Mehta J Thalidomide in cancer - Potential uses and limitations | 12 | 16 |
| 2165 | 54 | 61 | 2043 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):4-12 Singhal S; Mehta J Thalidomide in cancer | 16 | 20 |
| 2166 | 10 | 37 | 1588 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1565-1571 Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeldis J; Barlogie B; Siegel D; Crowley J Antitumor activity of thalidomide in refractory multiple myeloma. | 284 | 548 |
| 2167 | 0 | 0 | 1414 1998 BLOOD 92(10):318A-318A Singhal S; Mehta J; Eddlemon P; Gray P; Cromer J; Desikan R; Ayers D; Siegel D; Munshi N; Anaissie E; Kantarjian H; Zeldis J; Barlogie B Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). | 0 | 20 |
| 2168 | 3 | 15 | 2572 2004 AMERICAN JOURNAL OF HEMATOLOGY 76(1):66-68 Sinisalo M; Hietaharju A; Sauranen J; Wirta O Thalidomide in POEMS syndrome: Case report | 0 | 0 |
| 2169 | 5 | 5 | 1195 1995 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 19(1):128-129 SIRE S; FRAISSE P; REY D; JACQUEMIN C; KEMPF G; PARTISANI M; LANG JM EFFECTIVENESS OF THALIDOMIDE IN THE TREATMENT OF ESOPHAGEAL ULCERS IN AIDS | 2 | 2 |
| 2170 | 0 | 0 | 1849 2001 BLOOD 98(11):222B-222B Sivaraman S; Venugopal P; Hu WY; Gladstone B; Galili N; Nair A; Manjali J; Mogongwa A; Zhao HP; Manson S; Preisler H Effect of thalidomide as a single agent on serum cytokine levels in patients with relapsed acute myeloid leukemia. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2171 | 0 | 0 | 1278 1996 JOURNAL OF INVESTIGATIVE DERMATOLOGY 106(4):845-845 Smith C; Friednash M; Nguyen C; Knauf T; Walsh P Failure of thalidomide as an anti-angiogenesis factor in a murine melanoma model | 2 | 3 |
| 2172 | 9 | 51 | 1297 1996 TERATOLOGY 54(3):126-134 Smith DM; Torres RD; Stephens TD Mesonephros has a role in limb development and is related to thalidomide embryopathy | 0 | 5 |
| 2173 | 2 | 2 | 920 1986 ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY 64(3):P66-P66 SMITH NJ; JENKINS JS; POWELL RJ; ALLEN BR; LITTLEWOOD SM; MAURICE PDL NERVE-CONDUCTION STUDIES IN PATIENTS TAKING THALIDOMIDE | 0 | 0 |
| 2174 | 6 | 9 | 157 1962 LIFE SCIENCES (7):333-336 SMITH RL; WILLIAMS RAD; WILLIAMS RT PHTHALOYLISOGLUTAMINE, A METABOLITE OF THALIDOMIDE | 2 | 3 |
| 2175 | 0 | 0 | 52 1962 AMERICAN ZOOLOGIST 2(4):559-559 SMITH TE; BERNDT WO; OLEARY JF; CAVANAUGH DJ THE INVITRO INHIBITORY EFFECT OF THALIDOMIDE ON THE CHICK EMBRYO | 0 | 0 |
| 2176 | 2 | 6 | 352 1965 PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON 58(7):491-& SMITHELL.RW THALIDOMIDE LEGACY | 0 | 12 |
| 2177 | 0 | 0 | 371 1966 CLINICAL PEDIATRICS 5(4):255-& SMITHELL.RW THALIDOMIDE SYNDROME - COMPREHENSIVE CARE | 0 | 1 |
| 2178 | 0 | 0 | 497 1970 ARCHIVES OF DISEASE IN CHILDHOOD 45(240):274-& SMITHELL.RW HAND AND FOOT PREFERENCE IN THALIDOMIDE CHILDREN | 0 | 2 |
| 2179 | 1 | 1 | 563 1973 BRITISH MEDICAL JOURNAL 1(5848):269-272 SMITHELL.RW DEFECTS AND DISABILITIES OF THALIDOMIDE CHILDREN | 0 | 27 |
| 2180 | 2 | 3 | 1421 1998 BRITISH MEDICAL JOURNAL 316(7125):149-149 Smithells D Dominant gene probably caused some of defects ascribed to thalidomide | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2181 | 9 | 10 | 1431 1998 DRUG SAFETY 19(5):339-341 Smithells D Does thalidomide cause second generation birth defects? | 4 | 4 |
| 2182 | 2 | 5 | 1458 1998 LANCET 351(9115):1591-1591 Smithells D Was the thalidomide tragedy preventable? | 0 | 0 |
| 2183 | 0 | 0 | 122 1962 LANCET 1(7229):591-& SMITHELLS RW THALIDOMIDE AND CONGENITAL ABNORMALITIES | 7 | 9 |
| 2184 | 6 | 18 | 128 1962 LANCET 1(7242):1270-& SMITHELLS RW THALIDOMIDE AND MALFORMATIONS IN LIVERPOOL | 24 | 47 |
| 2185 | 1 | 2 | 675 1978 LANCET 1(8072):1042-1042 SMITHELLS RW THALIDOMIDE, ABSENT APPENDIX, AND SWEATING | 2 | 4 |
| 2186 | 2 | 2 | 1131 1994 BRITISH MEDICAL JOURNAL 309(6952):477-477 SMITHELLS RW THALIDOMIDE MAY BE A MUTAGEN | 8 | 9 |
| 2187 | 5 | 20 | 238 1963 LANCET 1(729):1095-& SMITHELLS RW; LECK I INCIDENCE OF LIMB AND EAR DEFECTS SINCE WITHDRAWAL OF THALIDOMIDE | 2 | 24 |
| 2188 | 8 | 18 | 1062 1992 JOURNAL OF MEDICAL GENETICS 29(10):716-723 SMITHELLS RW; NEWMAN CGH RECOGNITION OF THALIDOMIDE DEFECTS | 9 | 25 |
| 2189 | 8 | 11 | 2296 2003 ADAMANTIADES-BEHCET'S DISEASE 528:585-589 Sohn S; Lee ES; Lee SI; Kim YA; Kwon HJ; Bang D; Lei S Therapeutic effect of thalidomide through cytokine and chemokine regulation in herpes simplex virus-induced Behcet's disease-like animal model | 0 | 0 |
| 2190 | 5 | 13 | 1255 1996 CLINICAL INFECTIOUS DISEASES 23(3):501-503 Soler RA; Howard M; Brink NS; Gibb D; Tedder RS; Nadal D Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide | 24 | 31 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2191 | 4 | 5 | 1238 1996 ARCHIVES OF DISEASE IN CHILDHOOD 74(1):64-65 Soler RA; Migliorati C; vanWaes H; Nadal D Thalidomide treatment of mucosal ulcerations in HIV infection | 11 | 14 |
| 2192 | 1 | 19 | 6 1960 BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY 15(1):111-116 SOMERS GF PHARMACOLOGICAL PROPERTIES OF THALIDOMIDE (ALPHA-PHTHALIMIDO GLUTARIMIDE) - NEW SEDATIVE HYPNOTIC DRUG | 52 | 71 |
| 2193 | 1 | 3 | 126 1962 LANCET 1(7235):912-& SOMERS GF THALIDOMIDE AND CONGENITAL ABNORMALITIES | 79 | 168 |
| 2194 | 0 | 0 | 190 1963 BIOCHEMICAL PHARMACOLOGY 12:47-& SOMERS GF THALIDOMIDE AND CONGENITAL MALFORMATIONS | 0 | 2 |
| 2195 | 0 | 0 | 192 1963 BIOCHEMICAL PHARMACOLOGY 12:246-& SOMERS GF THALIDOMIDE AND CONGENITAL MALFORMATIONS | 0 | 2 |
| 2196 | 0 | 0 | 2397 2003 BLOOD 102(11):985A-986A Somlo G; Yamamoto N; Carter N; O'Donnell M; Snyder D; Sahebi F; Krishnan A; Fung H; Stein A; Spielberger R; Schriber J; Alvarnas J; Chow W; Nademance A; Jasmine Z; Stephen F High complete response rate is associated with improved progression-free and overall survival in 104 patients with multiple myeloma, treated with tandem cycle high-dose melphalan and busulfan/cytoxan, and maintenance interferon alpha-2 (IF) with, or without thalidomide (Thai) | 0 | 0 |
| 2197 | 0 | 0 | 1872 2001 BLOOD 98(11):685A-685A Somlo G; Yamamoto N; Sarah C; O'Donnell M; Snyder D; Sahebi F; Kogut N; Spielberger R; Molina A; Parker P; Popplewell L; Fung H; Rodriguez R; Stein A; Krishnan A; Chow W; Lopez F; Forman S Tandem cycle high-dose melphalan and intravenous busulfan/cytoxan with peripheral blood progenitor cell rescue (PBPC) followed by interferon alpha-2 (IF) with, or without thalidomide (Thal) for multiple myeloma. High complete response rate and moderate toxicities. | 0 | 1 |
| 2198 | 10 | 55 | 1473 1998 PAIN 74(1):83-91 Sommer C; Marziniak M; Myers RR The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve | 5 | 54 |
| 2199 | 2 | 32 | 2239 2002 JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 24(6):488-491 Soni S; Lee DS; DiVito J; Bui AH; DeRaffele G; Radel E; Kaufman HL Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide | 0 | 1 |
| 2200 | 1 | 18 | 664 1978 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 28-2(9):1567-1570 SONNENBICHLER J; LULING L STUDIES ON POSSIBLE INTERACTIONS OF THALIDOMIDE AND GENETIC MATERIAL FROM CHICKEN EMBRYOS | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2201 | 5 | 11 | 361 1966 AMERICAN JOURNAL OF NURSING 66(9):2023-2026 SOULES BJ THALIDOMIDE VICTIMS IN A REHABILITATION CENTER | 0 | 0 |
| 2202 | 5 | 6 | 117 1962 LANCET 1(7224):303-& SPEIRS AL THALIDOMIDE AND CONGENITAL ABNORMALITIES | 33 | 76 |
| 2203 | 0 | 1 | 343 1965 LANCET 2(7421):1074-& SPEIRS AL THALIDOMIDE | 0 | 0 |
| 2204 | 0 | 0 | 2363 2003 BLOOD 102(11):383B-384B Spencer A; Roberts A; Bailey M; Schran H; Lynch K No evidence for an adverse interaction between zoledronic acid and thalidomide: Preliminary safety analysis from the Australasian Leukaemia and Lymphoma Group (ALLG) MM6 myeloma trial. | 0 | 0 |
| 2205 | 0 | 0 | 2589 2004 BONE 34:S97-S97 Spencer A; Roberts A; Bailey M; Schran H; Lynch K Safety and pharmacokinetic analysis of zoledronic acid in a multicentre randomised trial of post-transplant thalidomide maintenance therapy for multiple myeloma | 0 | 0 |
| 2206 | 0 | 0 | 131 1962 LANCET 2(7246):100-& SPENCER KEV THALIDOMIDE AND CONGENITAL ABNORMALITIES | 18 | 31 |
| 2207 | 0 | 0 | 734 1980 TERATOLOGY 21(2):A71-A71 SPENCER MP; THEISEN CT THALIDOMIDE AND DEVELOPMENT OF SENSORY GANGLIA | 0 | 0 |
| 2208 | 0 | 0 | 1556 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S224-S224 Spraul CW; Kaven C; Amann J; Lang GK; Lang GE Effect of thalidomide, octreotide, and decortine on the migration and proliferation of RPE cells in vitro | 0 | 0 |
| 2209 | 3 | 44 | 1533 1999 CURRENT EYE RESEARCH 19(6):483-490 Spraul CW; Kaven C; Kampmeier J; Lang GK; Lang GE Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro | 5 | 9 |
| 2210 | 0 | 0 | 1730 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Spraul CW; Kaven C; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human RPE cell proliferation. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2211 | 9 | 23 | 2267 2002 MEDICAL ONCOLOGY 19(4):219-226 Srkalovic G; Elson P; Trebisky B; Karam MA; Hussein MA Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma | 1 | 2 |
| 2212 | 0 | 0 | 1508 1999 BLOOD 94(10):314B-315B Srkalovic G; Karam MA; McLain DA; Hussein MA Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM). | 0 | 1 |
| 2213 | 0 | 0 | 1657 2000 BLOOD 96(11):294B-295B Srkalovic G; Karam MA; Trebisky BM; Hussein MA Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD). | 0 | 1 |
| 2214 | 1 | 10 | 2306 2003 AMERICAN JOURNAL OF MEDICINE 115(4):332-334 Staak JO; Glossmann JP; Esser JM; Diehl V; Mietz H; Josting A Thalidomide for systemic capillary leak syndrome | 0 | 0 |
| 2215 | 2 | 27 | 461 1968 INTERNATIONAL DENTAL JOURNAL 18(3):631-& STAHL A CLINICAL ORTHODONTIC AND RADIOLOGICAL FINDINGS IN JAWS AND FACE OF CHILDREN WITH DYSMELIA ASSOCIATED WITH THALIDOMIDE-EMBRYOPATHY | 3 | 0 |
| 2216 | 0 | 0 | 1377 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 355(4):545-545 Stahl W; Nicolai S; Sies H Stimulation of gap junctional communication by thalidomide and thalidomide analogs in human skin fibroblasts | 0 | 0 |
| 2217 | 0 | 16 | 438 1967 LANCET 2(7509):242-& STAINSBY GD; QUIBELL EP PERTHES-LIKE CHANGES IN HIPS OF CHILDREN WITH THALIDOMIDE DEFORMITIES | 0 | 2 |
| 2218 | 5 | 5 | 1461 1998 LANCET 352(9127):544-545 Stambe C; Wicks IP TNF alpha and response of treatment-resistant adult-onset Still's disease to thalidomide | 10 | 24 |
| 2219 | 0 | 0 | 584 1973 TERATOLOGY 7(3):A28-A28 STAPLES RE; KLUMPP G TERATOGENIC RESPONSE TO LOW DOSAGES OF THALIDOMIDE IN RABBIT | 0 | 0 |
| 2220 | 2 | 8 | 2294 2003 ACTA DERMATO-VENEREOLOGICA 83(4):302-303 Staumont-Salle D; Magro L; Piette F; Thomas P; Jouet JP; Catteau B Chronic graft-versus-host disease revealed by lichenoid vulvar lesions successfully treated with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2221 | 0 | 0 | 1682 2000 BRITISH JOURNAL OF CANCER 83:31-31 Stebbing J; Benson C; Eisen T; Mak I; Pyle L; Smalley K; Gore ME A phase II study of high dose oral thalidomide in patients with metastatic renal cell carcinoma (RCC) or metastatic melanoma (MM) | 0 | 0 |
| 2222 | 16 | 37 | 1883 2001 BRITISH JOURNAL OF CANCER 85(7):953-958 Stebbing J; Benson C; Eisen T; Pyle L; Smalley K; Bridle H; Mak I; Sapunar F; Ahern R; Gore ME The treatment of advanced renal cell cancer with high-dose oral thalidomide | 18 | 30 |
| 2223 | 0 | 0 | 1928 2001 GASTROENTEROLOGY 120(5):A278-A278 Stein DJ; Rafiee P; Taras A; Lamirand TH; Fisher PJ; Ogawa H; Telford GL; Otterson MF; Johnson CP; Binion DG Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). | 0 | 0 |
| 2224 | 19 | 36 | 2528 2003 LEUKEMIA & LYMPHOMA 44(9):1489-1493 Steins MB; Bieker R; Padro T; Kessler T; Kienast J; Berdel WE; Mesters RM Thalidomide for the treatment of acute myeloid leukemia | 0 | 0 |
| 2225 | 19 | 36 | 2053 2002 BLOOD 99(3):834-839 Steins MB; Padro T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM Efficacy and safety of thalidomide in patients with acute myeloid leukemia | 10 | 24 |
| 2226 | 0 | 1 | 570 1973 JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY AND ALLIED DISCIPLINES 14(3):236-237 STEPHEN E ABNORMALITY AND NORMALITY - MOTHERING OF THALIDOMIDE CHILDREN - ROSKIES,E | 0 | 0 |
| 2227 | 1 | 2 | 1901 2001 CHEMISTRY IN BRITAIN 37(11):38-40 Stephens T Reinventing thalidomide | 0 | 1 |
| 2228 | 31 | 61 | 983 1988 TERATOLOGY 38(3):229-239 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 40 | 63 |
| 2229 | 4 | 12 | 1031 1990 TERATOLOGY 41(2):241-242 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 2230 | 4 | 10 | 1033 1990 TERATOLOGY 41(2):245-246 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 1 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2231 | 36 | 174 | 1629 2000 BIOCHEMICAL PHARMACOLOGY 59(12):1489-1499 Stephens TD; Bunde CJW; Fillmore BJ Mechanism of action in thalidomide teratogenesis | 24 | 36 |
| 2232 | 11 | 41 | 1793 2000 TERATOLOGY 61(3):189-195 Stephens TD; Fillmore BJ Hypothesis: Thalidomide embryopathy - Proposed mechanism of action | 17 | 30 |
| 2233 | 0 | 0 | 767 1981 TERATOLOGY 23(2):A63-A64 STEPHENS TD; MCNULTY TR IS THALIDOMIDE EMBRYOPATHY A RESULT OF NEUROPATHY - NO | 0 | 0 |
| 2234 | 11 | 28 | 620 1976 DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY 18(2):189-197 STEPHENSON JBP EPILEPSY - NEUROLOGICAL COMPLICATION OF THALIDOMIDE EMBRYOPATHY | 7 | 11 |
| 2235 | 0 | 0 | 565 1973 CLINICAL PHARMACOLOGY & THERAPEUTICS 14(4):660-661 STERN L LESSON OF THALIDOMIDE | 0 | 2 |
| 2236 | 12 | 32 | 941 1987 ARCHIVES OF TOXICOLOGY 60(5):376-381 STERZ H; NOTHDURFT H; LEXA P; OCKENFELS H TERATOLOGIC STUDIES ON THE HIMALAYAN RABBIT - NEW ASPECTS OF THALIDOMIDE-INDUCED TERATOGENESIS | 6 | 10 |
| 2237 | 14 | 24 | 2681 2004 ONKOLOGIE 27(2):150-154 Steurer M; Spizzo G; Mitterer M; Gastl G Low-dose thalidomide for multiple myeloma: Interim analysis of a compassionate use program | 0 | 0 |
| 2238 | 5 | 12 | 2413 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(1):101-103 Steurer M; Sudmeier I; Stauder R; Gastl G Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha | 3 | 5 |
| 2239 | 24 | 33 | 1285 1996 LUPUS 5(4):257-258 Stevens RJ The place of thalidomide in the treatment of inflammatory disease | 3 | 5 |
| 2240 | 0 | 0 | 1241 1996 ARTHRITIS AND RHEUMATISM 39(9):1352-1352 Stevens RJ; Andujar C; Edwards C; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2241 | 19 | 23 | 1319 1997 BRITISH JOURNAL OF RHEUMATOLOGY 36(3):353-359 Stevens RJ; Andujar C; Edwards CJ; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients | 36 | 49 |
| 2242 | 0 | 0 | 1761 2000 MOLECULAR BIOLOGY OF THE CELL 11:112A-112A Stevenson AN; Odoms S; Ezell T; Valentine S; Taylor L Does thalidomide reduce inflammation by altering cell adhesion molecule expression and cell-cell contacts on CEM cells? | 0 | 0 |
| 2243 | 0 | 0 | 26 1961 BRITISH MEDICAL JOURNAL 2(526):1223-& STEVENSON JS NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 0 | 4 |
| 2244 | 0 | 0 | 194 1963 BRITISH MEDICAL JOURNAL (532):123-& STEWART A CONGENITAL DEFECTS DUE TO THALIDOMIDE | 0 | 0 |
| 2245 | 5 | 5 | 1215 1995 MOLECULAR MEDICINE TODAY 1(5):210-210 STEWART A IS THALIDOMIDE A MUTAGEN | 0 | 0 |
| 2246 | 16 | 17 | 2011 2001 SEMINARS IN ONCOLOGY 28(6):602-606 Stirling D Thalidomide: A novel template for anticancer drugs | 7 | 12 |
| 2247 | 79 | 87 | 1478 1998 SEMINARS IN CUTANEOUS MEDICINE AND SURGERY 17(4):231-242 Stirling DI Thalidomide and its impact in dermatology | 14 | 17 |
| 2248 | 61 | 96 | 1785 2000 SEMINARS IN HEMATOLOGY 37(1):5-14 Stirling DI Pharmacology of thalidomide | 21 | 23 |
| 2249 | 16 | 29 | 477 1969 ARZNEIMITTEL-FORSCHUNG 19(2):167-& STOCKING.L; KOCH H TERATOLOGY STUDY ON A NEW COMPOUND (K-2004) WITH SEDATIVE-HYPNOTIC ACTIVITY AND STRUCTURALLY RELATED TO THALIDOMIDE | 0 | 20 |
| 2250 | 0 | 0 | 2244 2002 JOURNAL OF PSYCHOPHYSIOLOGY 16(4):249-250 Stoeckel MC; Pollock B; Stoerig P; Witte OW; Schnitzler A; Seitz RJ Mislocalizations across toes as evidence for sensorimotor plasticity in thalidomide embryopathy | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2251 | 0 | 37 | 2623 2004 EXPERIMENTAL BRAIN RESEARCH 156(3):333-341 Stoeckel MC; Pollok B; Schnitzler A; Witte OW; Seitz RJ Use-dependent cortical plasticity in thalidomide-induced upper extremity dysplasia: evidence from somaesthesia and neuroimaging | 0 | 0 |
| 2252 | 3 | 5 | 621 1976 EXPERIENTIA 32(5):597-599 STOKES PA; LYKKE AWJ; MCBRIDE WG ULTRASTRUCTURAL CHANGES IN DORSAL ROOT-GANGLIA EVOKED BY THALIDOMIDE IN RABBITS | 0 | 3 |
| 2253 | 0 | 0 | 705 1979 IRCS MEDICAL SCIENCE-BIOCHEMISTRY 7(9):451-451 STOKES PA; VARDY PH; MCBRIDE WG; LONG MA DISTRIBUTION OF THALIDOMIDE WITHIN EMBRYONIC-TISSUES | 2 | 2 |
| 2254 | 34 | 59 | 2126 2002 BLOOD REVIEWS 16(4):207-215 Strasser K; Ludwig H Thalidomide treatment in multiple myeloma | 3 | 4 |
| 2255 | 0 | 0 | 2410 2003 BRITISH JOURNAL OF DERMATOLOGY 149:81-81 Strauss RM; Bate J; Clayton T; Gooi J; Darling J; Newton-Bishop JA A child with laryngo-onycho-cutaneous syndrome successfully treated with thalidomide | 0 | 0 |
| 2256 | 27 | 28 | 1970 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(3):322-324 Strauss RS; Das FM Thalidomide-induced sensory neuropathy | 2 | 3 |
| 2257 | 3 | 4 | 1057 1992 GENITOURINARY MEDICINE 68(6):424-425 STRAZZI S; LEBBE C; GEOFFRAY C; ABLON G; MOREL P; VEROLA O; MOLINA JM APHTHOUS ULCERS IN HIV-INFECTED PATIENTS - TREATMENT WITH THALIDOMIDE | 8 | 10 |
| 2258 | 0 | 1 | 760 1981 POLITICAL QUARTERLY 52(1):135-136 STREET H THE SUNDAY-TIMES THALIDOMIDE CASE - CONTEMPT OF COURT AND THE FREEDOM OF THE PRESS - ROSEN,M | 0 | 0 |
| 2259 | 8 | 31 | 1058 1992 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 230(2):140-149 STROMLAND K; MILLER MT REFRACTIVE EVALUATION IN THALIDOMIDE EMBRYOPATHY | 3 | 5 |
| 2260 | 11 | 33 | 1082 1993 ACTA OPHTHALMOLOGICA 71(2):238-245 STROMLAND K; MILLER MT THALIDOMIDE EMBRYOPATHY - REVISITED 27 YEARS LATER | 4 | 12 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2261 | 7 | 19 | 1139 1994 DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY 36(4):351-356 STROMLAND K; NORDIN V; MILLER M; AKERSTROM B; GILLBERG C AUTISM IN THALIDOMIDE EMBRYOPATHY - A POPULATION STUDY | 3 | 71 |
| 2262 | 23 | 35 | 2289 2002 TERATOLOGY 66(3):115-121 Stromland K; Philipson E; Gronlund MA Offspring of male and female parents with thalidomide embryopathy: Birth defects and functional anomalies | 1 | 3 |
| 2263 | 5 | 24 | 2255 2002 LEUKEMIA & LYMPHOMA 43(1):133-137 Strupp C; Aivado M; Germing U; Gattermann N; Haas R Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: Two case reports | 1 | 4 |
| 2264 | 7 | 22 | 2253 2002 LEUKEMIA 16(1):1-6 Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N Thalidomide for the treatment of patients with myelodysplastic syndromes | 14 | 25 |
| 2265 | 16 | 28 | 2619 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(1):52-57 Strupp C; Germing U; Scherer A; Kundgen A; Modder U; Gattermann N; Haas R Thalidomide for the treatment of idiopathic myelofibrosis | 0 | 0 |
| 2266 | 5 | 8 | 2517 2003 LEUKEMIA 17(6):1200-1202 Strupp C; Hildebrandt B; Germing U; Haas R; Gattermann N Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome | 0 | 1 |
| 2267 | 2 | 10 | 283 1964 GANN 55(1):57-& SUGIURA K; WUEST HM EFFECT OF THALIDOMIDE ON TRANSPLANTABLE MOUSE RAT + HAMSTER TUMORS | 1 | 6 |
| 2268 | 0 | 0 | 683 1978 TERATOLOGY 18(1):137-137 SUGIURA Y ROENTGENOGRAPHIC CLASSIFICATION OF REDUCTION ANOMALIES OF UPPER LIMBS IN THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 2269 | 9 | 31 | 2431 2003 CHEMICAL & PHARMACEUTICAL BULLETIN 51(9):1098-1102 Suizu M; Muroya Y; Kakuta H; Kagechika H; Tanatani A; Nagasawa K; Hashimoto Y Cyclooxygenase inhibitors derived from thalidomide | 2 | 2 |
| 2270 | 0 | 0 | 1391 1998 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 216:U267-U267 Swartz GM; Shah JH; Fogler WE; Papathanassiu A; Madsen JW; Green SJ 2-methyl-2-phthalimidino-glutaric acid, a partially-reduced analog of thalidomide, is a potent inhibitor of B16 melanoma metastases. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2271 | 0 | 0 | 99 1962 ECONOMIST 204(9):769-769 SWEETMAN WP AFTER THALIDOMIDE | 0 | 0 |
| 2272 | 0 | 0 | 228 1963 LANCET 1(727):501-& SWEETNAM WP THALIDOMIDE AND NEED TO LABEL DRUGS | 0 | 0 |
| 2273 | 0 | 0 | 33 1961 BRITISH MEDICAL JOURNAL 2(526):1498-& SWIFT EF NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 1 | 1 |
| 2274 | 0 | 7 | 575 1973 LANCET 2(7835):966-966 SWIFT TR THALIDOMIDE IN ERYTHEMA-NODOSUM LEPROSUM | 0 | 0 |
| 2275 | 11 | 27 | 415 1967 AMERICAN JOURNAL OF VETERINARY RESEARCH 28(127):1823-& SZABO KT; STEELMAN RL EFFECTS OF MATERNAL THALIDOMIDE TREATMENT ON PREGNANCY FETAL DEVELOPMENT AND MORTALITY OF OFFSPRING IN RANDOM-BRED MICE | 12 | 12 |
| 2276 | 3 | 27 | 416 1967 AMERICAN JOURNAL OF VETERINARY RESEARCH 28(127):1829-& SZABO KT; STEELMAN RL EFFECTS OF THALIDOMIDE TREATMENT OF INBRED FEMALE MICE ON PREGNANCY FETAL DEVELOPMENT AND MORTALITY OF OFFSPRING | 2 | 2 |
| 2277 | 0 | 62 | 667 1978 FOLIA HISTOCHEMICA ET CYTOCHEMICA 16(3):233-& SZYDLOWSKA H; DLUZNIEWSKI A APPLICATION OF THALIDOMIDE AS A BLOCK OF FUNCTIONAL-GROUPS OF PROTEINS IN HISTOCHEMICAL INVESTIGATIONS | 0 | 0 |
| 2278 | 3 | 9 | 1467 1998 NATURE 396(6709):322-323 Tabin CJ A developmental model for thalidomide defects | 9 | 20 |
| 2279 | 2 | 12 | 1583 1999 NATURE 400(6743):420-420 Tabin CJ Developmental model for thalidomide action - Reply | 0 | 0 |
| 2280 | 21 | 57 | 219 1963 HIROSHIMA JOURNAL OF MEDICAL SCIENCES 12(1):11-& TABUCHI A; SAWASAKI M; UMISA H; SHIRASUN.K; HORIKAWA M; YAMADA A; SHINTANI T PHOCOMELIA-LIKE DEFORMITY AND THALIDOMIDE PREPARATIONS | 3 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2281 | 9 | 20 | 2510 2003 LEPROSY REVIEW 74(3):206-214 Tadesse A; Taye E; Sandoval F; Shannow EJ Thalidomide does not modify the ability of cells in leprosy patients to incorporate [H-3]-thymidine when incubated with M-leprae antigens | 0 | 0 |
| 2282 | 0 | 5 | 618 1976 ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY 102(7):425-427 TAKEMORI S; TANAKA Y; SUZUKI JI THALIDOMIDE ANOMALIES OF EAR | 5 | 12 |
| 2283 | 19 | 39 | 1591 1999 ORGANIC LETTERS 1(10):1571-1573 Takeuchi Y; Shiragami T; Kimura K; Suzuki E; Shibata N (R)- and (S)-3-fluorothalidomides: Isosteric analogues of thalidomide | 3 | 13 |
| 2284 | 11 | 26 | 1035 1990 TRANSPLANTATION 49(1):20-25 TAMURA F; VOGELSANG GB; REITZ BA; BAUMGARTNER WA; HERSKOWITZ A COMBINATION THALIDOMIDE AND CYCLOSPORINE FOR CARDIAC ALLOGRAFT-REJECTION - COMPARISON WITH COMBINATION METHYLPREDNISOLONE AND CYCLOSPORINE | 20 | 26 |
| 2285 | 4 | 7 | 326 1965 CHEMICAL & PHARMACEUTICAL BULLETIN 13(10):1263-& TANAKA A; HASEGAWA A; URAKUBO G METABOLIC FATE OF THALIDOMIDE IN RATS | 6 | 7 |
| 2286 | 0 | 0 | 867 1984 TERATOLOGY 30(1):A36-A36 TANAKA Y THALIDOMIDE-INDUCED OTOLARYNGOLOGICAL DEFECTS | 0 | 0 |
| 2287 | 0 | 0 | 533 1971 TERATOLOGY 4(2):247-& TANIMURA T; TANAKA O; NISHIMUR.H EFFECTS OF THALIDOMIDE AND QUINE DIHYDROCHLORIDE ON JAPANESE AND RHESUS MONKEY EMBRYOS | 2 | 5 |
| 2288 | 5 | 14 | 295 1964 NATURE 204(496):939-& TATA JR THALIDOMIDE + INDUCED AMPHIBIAN METAMORPHOSIS | 2 | 3 |
| 2289 | 0 | 3 | 2670 2004 MEDICAL JOURNAL OF AUSTRALIA 180(4):200-200 Tattersall MHN Licensing thalidomide in Australia - Reply | 0 | 0 |
| 2290 | 0 | 0 | 50 1962 AMERICAN JOURNAL OF DISEASES OF CHILDREN 104(2):111-& TAUSSIG HB THALIDOMIDE-A LESSON IN REMOTE EFFECTS OF DRUGS | 0 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2291 | 0 | 0 | 51 1962 AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 84(7):979-& TAUSSIG HB PHOCOMELIA AND THALIDOMIDE | 0 | 0 |
| 2292 | 0 | 0 | 94 1962 CIRCULATION 26(4):795-& TAUSSIG HB THALIDOMIDE AND PHOCOMELIA | 0 | 0 |
| 2293 | 6 | 18 | 102 1962 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 180(13):1106-& TAUSSIG HB A STUDY OF GERMAN OUTBREAK OF PHOCOMELIA - THALIDOMIDE SYNDROME | 37 | 127 |
| 2294 | 0 | 0 | 104 1962 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 181(7):654-& TAUSSIG HB THALIDOMIDE AND RELATED COMPOUNDS - REPLY | 0 | 0 |
| 2295 | 5 | 14 | 171 1962 PEDIATRICS 30(4):654-& TAUSSIG HB THALIDOMIDE AND PHOCOMELIA | 2 | 12 |
| 2296 | 2 | 4 | 179 1962 SCIENTIFIC AMERICAN 207(2):29-& TAUSSIG HB THALIDOMIDE SYNDROME | 7 | 15 |
| 2297 | 5 | 10 | 251 1963 NEW ENGLAND JOURNAL OF MEDICINE 269(2):92-& TAUSSIG HB EVILS OF CAMOUFLAGE AS ILLUSTRATED BY THALIDOMIDE | 1 | 5 |
| 2298 | 5 | 32 | 1384 1997 RESPIRATORY MEDICINE 91(1):31-39 Tavares JL; Wangoo A; Dilworth P; Marshall B; Kotecha S; Shaw RJ Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages | 23 | 38 |
| 2299 | 0 | 0 | 1580 1999 MOLECULAR BIOLOGY OF THE CELL 10:75A-75A Taylor LD; Settles B; Wilson K; Mack C Investigation of the inhibition of cell adhesion by the Anti-TNF-alpha agent thalidomide utilizing in vitro fluorescence-based assays. | 0 | 0 |
| 2300 | 1 | 3 | 1678 2000 BLOOD 96(12):4007-4007 Tefferi A; Elliott MA Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia | 15 | 23 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2301 | 3 | 5 | 1151 1994 LANCET 344(8916):196-197 TEIXEIRA F; HOJYO MT; ARENAS R; VEGA ME; CORTES R; ORTIZ A; DOMINGUEZ L THALIDOMIDE - CAN IT CONTINUE TO BE USED | 4 | 4 |
| 2302 | 7 | 10 | 2531 2003 LUPUS 12(9):723-724 Tektonidou MG; Vlachoyiannopoulos PG Antiphospholipid syndrome triggered by thalidomide in a patient with discoid lupus erythematosus | 0 | 0 |
| 2303 | 3 | 5 | 1133 1994 BRITISH MEDICAL JOURNAL 309(6966):1442-1442 TENCONI R; CLEMENTI M; NOTARI L; VASCO VRLO AMNIOTIC BAND SEQUENCE IN CHILD OF THALIDOMIDE VICTIM | 4 | 6 |
| 2304 | 22 | 40 | 1723 2000 HUMAN & EXPERIMENTAL TOXICOLOGY 19(11):615-622 Teo S; Evans M; Ehrhart J; Brockman M; Allen D; Morgan M; Stirling D; Thomas S Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules | 0 | 0 |
| 2305 | 16 | 22 | 1792 2000 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(5):301-311 Teo S; Morgan M; Stirling D; Thomas S Assessment of the in vitro and in vivo genotoxicity of Thalomid (R) (Thalidomide) | 1 | 1 |
| 2306 | 7 | 11 | 2017 2002 AIDS 16(17):2355-2356 Teo S; Noormohamed F; Youle M; Johnson M; Peters B; Stirling D; Thomas S Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing | 1 | 1 |
| 2307 | 18 | 24 | 2216 2002 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 767(1):145-151 Teo SK; Chandula RS; Harden JL; Stirling DI; Thomas SD Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry | 3 | 4 |
| 2308 | 12 | 15 | 1562 1999 JOURNAL OF CLINICAL PHARMACOLOGY 39(11):1162-1168 Teo SK; Colburn WA; Thomas SD Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers | 19 | 19 |
| 2309 | 52 | 65 | 2613 2004 CLINICAL PHARMACOKINETICS 43(5):311-327 Teo SK; Colburn WA; Tracewell WG; Kook KA; Stirling DI; Jaworsky MS; Scheffler MA; Thomas SD; Laskin OL Clinical pharmacokinetics of thalidomide | 0 | 0 |
| 2310 | 27 | 47 | 2588 2004 BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY 71(1):1-16 Teo SK; Denny KH; Stirling DI; Thomas SD; Morseth SL; Hoberman AM Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2311 | 32 | 52 | 2014 2001 TOXICOLOGICAL SCIENCES 59(1):160-168 Teo SK; Evans MG; Brockman MJ; Ehrhart J; Morgan JM; Stirling DI; Thomas SD Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs | 4 | 4 |
| 2312 | 8 | 13 | 1918 2001 DRUG METABOLISM AND DISPOSITION 29(10):1355-1357 Teo SK; Harden JL; Burke AB; Noormohamed FH; Youle M; Johnson MA; Peters BS; Stirling DI; Thomas SD Thalidomide is distributed into human semen after oral dosing | 7 | 12 |
| 2313 | 7 | 38 | 2268 2002 MICROBES AND INFECTION 4(11):1193-1202 Teo SK; Resztak KE; Scheffler MA; Kook KA; Zeldis JB; Stirling DI; Thomas SD Thalidomide in the treatment of leprosy | 7 | 9 |
| 2314 | 20 | 25 | 1735 2000 JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY 14(3):140-147 Teo SK; Sabourin PJ; O'Brien K; Kook KA; Thomas SD Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients | 21 | 21 |
| 2315 | 15 | 33 | 1631 2000 BIOPHARMACEUTICS & DRUG DISPOSITION 21(1):33-40 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women | 6 | 6 |
| 2316 | 22 | 32 | 1960 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(6):662-667 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Thalidomide dose proportionality assessment following single doses to healthy subjects | 3 | 4 |
| 2317 | 18 | 29 | 1554 1999 INTERNATIONAL JOURNAL OF TOXICOLOGY 18(5):337-352 Teo SK; Trigg NJ; Shaw ME; Morgan JM; Thomas SD Subchronic toxicity of thalidomide in rodents after 13 weeks of oral administration | 6 | 6 |
| 2318 | 1 | 2 | 652 1977 LANCET 2(8034):405-405 TEPPO L; SAXEN E; TERVO T; PARTIO E; VONBONSDORFF H; SALMELA J; AVIKAINEN V; ISOMAKI M; KREES R THALIDOMIDE-TYPE MALFORMATIONS AND SUBSEQUENT OSTEOSARCOMA | 2 | 2 |
| 2319 | 2 | 7 | 1295 1996 REVISTA CLINICA ESPANOLA 196(4):270-271 Tercedor J; delaTorre ML; Rodenas JM Disseminated xanthoma with insipid diabetes: Therapeutic failure of thalidomide | 0 | 0 |
| 2320 | 0 | 0 | 1049 1991 MEDICINA CLINICA 97(2):79-79 TERCEDOR J; ORTEGO N; RODENAS JM; HERNANDEZ J TREATMENT OF RECURRENT APHTHAE WITH THALIDOMIDE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2321 | 0 | 0 | 908 1985 TERATOLOGY 31(3):A68-A68 TESH JM; NEWALL DR TERATOGENIC EFFECTS OF THALIDOMIDE ON RAT EMBRYOS INVITRO | 0 | 1 |
| 2322 | 0 | 0 | 931 1986 TERATOLOGY 33(2):A48-A49 TESH JM; NEWALL DR THALIDOMIDE AND ABNORMAL EMBRYONIC-DEVELOPMENT INVITRO | 0 | 0 |
| 2323 | 8 | 26 | 1399 1998 ARCHIV DER PHARMAZIE 331(1):7-12 Teubert U; Zwingenberger K; Wnendt S; Eger K 5 '-substituted thalidomide analogs as modulators of TNF-alpha | 10 | 10 |
| 2324 | 0 | 0 | 1732 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S684-S684 Tham VMB; Tong JT; Giese MJ; Tran MK; Fardin B; Taban R; Rayner SA; Mondino BJ The effect of thalidomide on corneal graft rejection in rabbit eyes | 0 | 0 |
| 2325 | 0 | 0 | 735 1980 TERATOLOGY 21(2):A72-A72 THEISEN CT THALIDOMIDE DYSMELIA - PROPOSED PATHOGENESIS | 0 | 1 |
| 2326 | 0 | 0 | 835 1983 TERATOLOGY 27(2):A80-A80 THEISEN CT THALIDOMIDE DYSMELIA IN RHESUS-MONKEYS - AN OVERVIEW | 0 | 0 |
| 2327 | 10 | 28 | 712 1979 TERATOLOGY 19(3):313-& THEISEN CT; BODIN JD; SVOBODA JA; PETTINELLI MW UNUSUAL MUSCLE ABNORMALITIES ASSOCIATED WITH THALIDOMIDE TREATMENT IN A RHESUS-MONKEY - CASE-REPORT | 0 | 2 |
| 2328 | 0 | 1 | 656 1977 TERATOLOGY 15(2):A24-A24 THEISEN CT; HABIGER T; SWARTWOOD LD; SCHMIDT HL; WILSON JG THALIDOMIDE DYSMELIA IN RHESUS-MONKEYS - EVIDENCE FOR A PRIMARY EFFECT ON SPINAL GANGLIA | 1 | 3 |
| 2329 | 0 | 0 | 768 1981 TERATOLOGY 23(2):A65-A65 THEISEN CT; MCGREGOR EE FURTHER OBSERVATIONS ON THE DEVELOPMENT OF THALIDOMIDE INDUCED LIMB DEFORMITIES | 4 | 7 |
| 2330 | 0 | 0 | 632 1976 TERATOLOGY 13(2):A39-A39 THEISEN CT; SCHMIDT LH; WILSON JG ANATOMY OF THALIDOMIDE DYSMELIA IN RHESUS-MONKEYS | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2331 | 0 | 0 | 680 1978 TERATOLOGY 17(2):A23-A23 THEISEN CT; SCHMIDT LH; WILSON JG UNUSUAL MUSCLE ABNORMALITIES PRODUCED BY THALIDOMIDE IN RHESUS-MONKEYS | 0 | 1 |
| 2332 | 0 | 0 | 711 1979 TERATOLOGY 19(2):A51-A51 THEISEN CT; SPENCER MP MORPHOLOGICAL OBSERVATIONS IN RHESUS-MONKEY EMBRYOS FOLLOWING MATERNAL THALIDOMIDE ADMINISTRATION | 2 | 3 |
| 2333 | 0 | 0 | 91 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 87(18):981-& THEORET JJ CHRONOLOGY OF THALIDOMIDE STORY | 0 | 0 |
| 2334 | 9 | 16 | 1756 2000 LIFE SCIENCES 66(2):133-141 Thiel R; Kastner U; Neubert R Expression of adhesion receptors on rat limb bud cells and results of treatment with a thalidomide derivative | 3 | 4 |
| 2335 | 0 | 0 | 1469 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 357(4):R119-R119 Thiel R; Klug S Adhesion receptors on rat limb bud cells after treatment with a thalidomide derivative | 0 | 0 |
| 2336 | 19 | 36 | 2181 2002 EUROPEAN JOURNAL OF PHARMACOLOGY 453(2-3):325-334 Thiele A; Bang R; Gutschow M; Rossol M; Loos S; Eger K; Tiegs G; Hauschildt S Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide | 1 | 3 |
| 2337 | 3 | 13 | 1757 2000 LIFE SCIENCES 67(4):457-461 Thiele A; Thormann M; Hofmann HJ; Naumann WW; Eger K; Hauschildt S A possible role of N-cadherin in thalidomide teratogenicity | 4 | 6 |
| 2338 | 5 | 7 | 553 1972 INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY 10(4):316-& THOMAS BP; VARIA MR; ANSARI MM; MEMON GN LACK OF THALIDOMIDE INDUCED APLASIA IN REGENERATING TAIL OF LIZARD, HEMIDACTYLUS-FLAVIVIRDIS | 0 | 0 |
| 2339 | 1 | 4 | 552 1972 INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY 10(4):314-& THOMAS BP; VARIA MR; MEMON GN; ANSARI MM EFFECT OF THALIDOMIDE ON LIVER REGENERATION IN RAT | 1 | 1 |
| 2340 | 8 | 35 | 1788 2000 SEMINARS IN HEMATOLOGY 37(1):26-34 Thomas DA Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders | 9 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2341 | 0 | 0 | 1515 1999 BLOOD 94(10):507A-507A Thomas DA; Aguayo A; Estey E; Albitar M; O'Brien S; Giles FJ; Beran M; Cortes J; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide as anti-angiogenesis therapy (RX) in refractory or relapsed leukemias. | 0 | 5 |
| 2342 | 0 | 0 | 1520 1999 BLOOD 94(10):702A-702A Thomas DA; Aguayo A; Giles FJ; Albitar M; O'Brien S; Cortes J; Faderl S; Bivins C; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF). | 0 | 15 |
| 2343 | 9 | 20 | 2420 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(3):436-441 Thomas DA; Estey E; Giles FJ; Faderl S; Cortes J; Keating M; O'Brien S; Albitar M; Kantarjian H Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia | 0 | 0 |
| 2344 | 49 | 95 | 1701 2000 CURRENT OPINION IN ONCOLOGY 12(6):564-573 Thomas DA; Kantarjian HM Current role of thalidomide in cancer treatment | 16 | 40 |
| 2345 | 22 | 30 | 1809 2001 ANNALS OF ONCOLOGY 12(7):885-886 Thomas DA; Kantarjian HM The revitalization of thalidomide | 4 | 5 |
| 2346 | 29 | 41 | 1084 1993 ARCHIVES OF DERMATOLOGY 129(10):1261-1264 THOMAS L; DUCROS B; SECCHI T; BALME B; MOULIN G SUCCESSFUL TREATMENT OF ADULTS LANGERHANS CELL HISTIOCYTOSIS WITH THALIDOMIDE - REPORT OF 2 CASES AND LITERATURE-REVIEW | 23 | 40 |
| 2347 | 16 | 25 | 2325 2003 ARCHIVES OF DERMATOLOGY 139(2):136-138 Thomas P; Walchner M; Ghoreschi K; Rocken M Successful treatment of granulomatous cheilitis with thalidomide | 0 | 0 |
| 2348 | 0 | 0 | 1209 1995 LANCET 346(8985):1289-1289 THOMPSON C THALIDOMIDE EFFECTIVE FOR AIDS-RELATED ORAL ULCERS | 5 | 10 |
| 2349 | 0 | 0 | 158 1962 MEDICAL JOURNAL OF AUSTRALIA 1(14):533-& THOMPSON HL CONGENITAL ABNORMALITIES AND THALIDOMIDE | 0 | 0 |
| 2350 | 10 | 33 | 2315 2003 ANNALS OF PHARMACOTHERAPY 37(4):571-576 Thompson JL; Hansen LA Thalidomide dosing in patients with relapsed or refractory multiple myelorna | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2351 | 4 | 10 | 2419 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(2):305-308 Thompson MA; Witzig TE; Kumar S; Timm MM; Haug J; Fonseca R; Greipp PR; Lust JA; Rajkumar SV Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma | 2 | 4 |
| 2352 | 0 | 0 | 2121 2002 BLOOD 100(11):811A-811A Thompson MA; Witzig TE; Timm MM; Haug J; Kumar S; Fonseca R; Greipp PR; Rajkumar SV Angiogenesis and angiogenic cytokines in patients receiving thalidomide for multiple myeloma (MM). | 0 | 1 |
| 2353 | 9 | 9 | 1962 2001 JOURNAL OF DERMATOLOGICAL TREATMENT 12(3):145-147 Thomson KF; Goodfield MJD Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus | 0 | 2 |
| 2354 | 0 | 68 | 1790 2000 SOCIAL STUDIES OF SCIENCE 30(1):41-71 Timmermans S; Leiter V The redemption of thalidomide: Standardizing the risk of birth defects | 0 | 1 |
| 2355 | 5 | 11 | 2409 2003 BRITISH JOURNAL OF DERMATOLOGY 148(5):1060-1061 Tjiu JW; Hsiao CH; Tsai TF Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment | 0 | 0 |
| 2356 | 19 | 58 | 274 1964 BIOCHEMICAL PHARMACOLOGY 13(11):1489-& TOIVANEN A; TOIVANEN P; MANTYJAR.R; MARKKANEN T MICROBIOLOGICALLY DETERMINED PANTOTHENIC ACID + NICOTINIC ACID CONTENT OF CHICK EMBRYOS AFTER TREATMENT WITH THALIDOMIDE + OF RAT FETUSES NEWBORNS + PLACENTAS FROM MOTHERS TREATED WITH THALIDOMIDE | 2 | 4 |
| 2357 | 0 | 0 | 141 1962 LANCET 2(7252):400-& TOMS DA; APPLEBEY M; HUNTER TAA; WOOLLAM DHM; ASHLEY DJB THALIDOMIDE AND CONGENITAL ABNORMALITIES | 4 | 6 |
| 2358 | 9 | 9 | 1561 1999 JOURNAL OF CHROMATOGRAPHY B 734(2):203-210 Torano JS; Verbon A; Guchelaar HJ Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection | 8 | 8 |
| 2359 | 0 | 2 | 776 1982 ARCHIVES OF DERMATOLOGY 118(11):875-875 TORRAS H; LECHA M; MASCARO JM THALIDOMIDE TREATMENT OF RECURRENT NECROTIC GIANT MUCOCUTANEOUS APHTHAE AND APHTHOSIS | 18 | 24 |
| 2360 | 18 | 23 | 2195 2002 HAEMATOLOGICA 87(3):233-234 Tosi P; Cavo M Thalidomide in multiple myeloma: state of art | 3 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2361 | 17 | 33 | 1938 2001 HAEMATOLOGICA 86(4):409-413 Tosi P; Ronconi S; Zamagni E; Cellini C; Grafone T; Cangini D; Pileri SA; Baccarani M; Tura S; Cavo M Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation | 13 | 21 |
| 2362 | 0 | 0 | 1660 2000 BLOOD 96(11):296B-296B Tosi P; Ronconi S; Zamagni E; Cellini C; Tura S; Cavo M Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma. | 0 | 3 |
| 2363 | 0 | 0 | 2365 2003 BLOOD 102(11):385B-386B Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Combined thalidomide-dexametasone and zoledronic acid induce a reduction of bone resorption markers in newly diagnosed multiple myeloma patients. | 0 | 0 |
| 2364 | 11 | 26 | 2621 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 73(2):98-103 Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure | 0 | 0 |
| 2365 | 0 | 0 | 1840 2001 BLOOD 98(11):163A-163A Tosi P; Zamagni E; Cellini C; Cangini D; Tura S; Baccarani M; Cavo M Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced relapsed and refractor multiple myeloma. | 0 | 3 |
| 2366 | 15 | 35 | 2199 2002 HAEMATOLOGICA 87(4):408-414 Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma | 19 | 28 |
| 2367 | 4 | 18 | 1214 1995 MOLECULAR MEDICINE 1(4):384-397 TRAMONTANA JM; UTAIPAT U; MOLLOY A; AKARASEWI P; BURROUGHS M; MAKONKAWKEYOON S; JOHNSON B; KLAUSNER JD; ROM W; KAPLAN G THALIDOMIDE TREATMENT REDUCES TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION AND ENHANCES WEIGHT-GAIN IN PATIENTS WITH PULMONARY TUBERCULOSIS | 60 | 130 |
| 2368 | 9 | 27 | 1429 1998 CLINICAL PHARMACOLOGY & THERAPEUTICS 64(6):597-602 Trapnell CB; Donahue SR; Collins JM; Flockhart DA; Thacker D; Abernethy DR Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone | 13 | 15 |
| 2369 | 4 | 40 | 2241 2002 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 27(3-4):497-505 Trapp O; Schoetz G; Schurig V Stereointegrity of thalidomide: gas-chromatographic determination of the enantiomerization barrier | 0 | 2 |
| 2370 | 0 | 0 | 1934 2001 GUT 48:A89-A90 Trebble T; Johns T; Duncan HD; Goggin PM An open trial of thalidomide in refractory Crohn's colitis | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2371 | 0 | 0 | 2124 2002 BLOOD 100(11):816A-816A Treston AM; Swartz GM; Conner B; Shah J; Pribluda VS Pre-clinical evaluation of a thalidomide analog with activity against multiple myeloma and solid tumors - ENMD-0995 (S-(-)3- (3-amino-phthalimido)-glutarimide). | 0 | 1 |
| 2372 | 2 | 6 | 861 1984 REVUE DU RHUMATISME 51(10):585-585 TREVES R; ARNAUD M; JACOB P; LUBEAU M; TABARAUD F; BURKI F; DESPROGESGOTTERON R DRAMATIC IMPROVEMENT IN THE ARTHRITIS OF BEHCETS-DISEASE FOLLOWING THE ADMINISTRATION OF THALIDOMIDE - A CASE-REPORT | 3 | 5 |
| 2373 | 0 | 23 | 572 1973 KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE 162(4):546-550 TRIESCHM.W CROCODILE TEARS IN THALIDOMIDE EMBRYOPATHY | 0 | 4 |
| 2374 | 3 | 4 | 2012 2001 SWISS MEDICAL WEEKLY 131(9-10):133-133 Trojan A; Anagnostara A; Fost L Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma | 2 | 2 |
| 2375 | 9 | 9 | 2314 2003 ANNALS OF ONCOLOGY 14(3):501-502 Trojan A; Chasse E; Gay B; Pichert G; Taverna C Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma | 2 | 2 |
| 2376 | 0 | 0 | 2593 2004 BONE MARROW TRANSPLANTATION 33:S161-S161 Trojan A; Giger R; Rist N; Jager D; Taverna C Thalidomide stimulates peptide specific CD8+T-cells against viral epitopes | 0 | 0 |
| 2377 | 0 | 0 | 155 1962 LANCET 2(7266):1162-& TRUETA J CARE OF THALIDOMIDE BABIES - EXPERIENCE IN GERMANY | 0 | 0 |
| 2378 | 0 | 0 | 143 1962 LANCET 2(7253):452-& TRUETA J; AGERHOLM M THALIDOMIDE-DAMAGED INFANTS | 1 | 1 |
| 2379 | 9 | 25 | 1117 1994 ARCHIVES OF DERMATOLOGICAL RESEARCH 286(6):347-349 TSAMBAOS D; BOLSEN K; GEORGIOU S; MONASTIRLI A; GOERZ G EFFECTS OF ORAL THALIDOMIDE ON RAT-LIVER AND SKIN MICROSOMAL P450 ISOZYME ACTIVITIES AND ON URINARY PORPHYRIN EXCRETION - INTERACTION WITH ORAL HEXACHLOROBENZENE | 14 | 15 |
| 2380 | 32 | 67 | 1896 2001 CANCER 92(9):2364-2373 Tseng JE; Glisson BS; Khuri FR; Shin DM; Myers JN; El-Naggar AK; Roach JS; Ginsberg LE; Thall PF; Wang XM; Teddy S; Lawhorn KN; Zentgraf RE; Steinhaus GD; Pluda JM; Abbruzzese JL; Hong WK; Herbst RS Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck | 6 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2381 | 86 | 101 | 1282 1996 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 35(6):969-979 Tseng S; Pak G; Washenik K; Pomeranz MK; Shupack JL Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses | 76 | 114 |
| 2382 | 9 | 36 | 2035 2002 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(6):1887-1895 Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis | 3 | 5 |
| 2383 | 0 | 1 | 2036 2002 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(7):2313-2313 Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis (vol 46, pg 1889, 2002) | 0 | 0 |
| 2384 | 9 | 41 | 1446 1998 JOURNAL OF INFECTIOUS DISEASES 177(6):1563-1572 Tsenova L; Sokol K; Freedman VH; Kaplan G Combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death | 14 | 26 |
| 2385 | 5 | 9 | 2295 2003 ACTA HAEMATOLOGICA 109(3):153-155 Tsiara S; Chaidos A; Kapsali H; Tzouvara E; Bourantas KL Thalidomide administration for the treatment of resistant plasma cell leukemia | 0 | 0 |
| 2386 | 3 | 5 | 2261 2002 LEUKEMIA RESEARCH 26(10):965-966 Tsirigotis P; Venetis E; Rontogianni D; Dervenoulas J; Kontopidou F; Apostolidis P Thalidomide in the treatment of myelodysplastic syndrome with fibrosis | 2 | 2 |
| 2387 | 0 | 0 | 793 1982 TERATOLOGY 26(1):A4-A4 TSUCHIYA K THALIDOMIDE EMBRYOPATHY AND ITS ALLIED CONDITIONS IN JAPAN | 0 | 0 |
| 2388 | 0 | 0 | 1273 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):572-572 Tsujikawa M; Saito Y; Tatebayashi M; Tano Y The inhibitory effect of thalidomide for experimental preretinal neovascularization by laser-induced venous occlusion in rats. | 0 | 0 |
| 2389 | 3 | 10 | 172 1962 PRESSE MEDICALE 70(31):1521-& TUCHMANNDUPLESSIS A PROPOS DES MALFORMATIONS ATTRIBUEES A UN SOMNIFERE LA THALIDOMIDE | 0 | 0 |
| 2390 | 0 | 0 | 2398 2003 BONE MARROW TRANSPLANTATION 31:S76-S77 Tueger S; Chen F; Ahsan G; Andrews V; Kazmi M; Madrigal J; Schey S Thalidomide-induced remission of refractory diffuse large B-cell lymphoma post-allogeneic SCT - a result of modulation of CTL function? | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2391 | 36 | 49 | 1914 2001 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1178-1182 Tuinmann G; Hegewisch-Becker S; Hossfeld DK New indications for thalidomide | 2 | 3 |
| 2392 | 0 | 0 | 164 1962 MEDICAL JOURNAL OF AUSTRALIA 2(14):567-& TUREK MA THALIDOMIDE SITUATION | 0 | 0 |
| 2393 | 13 | 32 | 1293 1996 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 93(15):7552-7556 Turk BE; Jiang H; Liu JO Binding of thalidomide to alpha(1)-acid glyeoprotein may be involved in its inhibition of tumor necrosis factor alpha production | 39 | 47 |
| 2394 | 3 | 10 | 395 1966 LANCET 1(7447):1134-& TURK JL; HELLMANN K; DUKE DI EFFECT OF THALIDOMIDE ON IMMUNOLOGICAL RESPONSE IN LOCAL LYMPH NODES AFTER A SKIN HOMOGRAFT | 28 | 32 |
| 2395 | 6 | 40 | 2468 2003 INTERNATIONAL JOURNAL OF HEMATOLOGY 78(5):443-449 Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide | 0 | 1 |
| 2396 | 0 | 0 | 1847 2001 BLOOD 98(11):182B-182B Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Yalcin A Terminal differentiation and apoptosis of myeloid leukemia induced by thalidomide and rhGM-CSF combination. | 0 | 0 |
| 2397 | 5 | 5 | 2054 2002 BLOOD 99(11):4247-4248 Urbauer E; Kaufmann H; Nosslinger T; Raderer M; Drach J Thromboembolic events during treatment with thalidomide | 12 | 17 |
| 2398 | 12 | 24 | 1169 1995 ANNALS OF THORACIC SURGERY 59(2):277-282 UTHOFF K; ZEHR KJ; GAUDIN PB; KUMAR P; CHO PW; VOGELSANG G; HRUBAN RH; BAUMGARTNER WA; STUART RS THALIDOMIDE AS REPLACEMENT FOR STEROIDS IN IMMUNOSUPPRESSION AFTER LUNG TRANSPLANTATION | 16 | 18 |
| 2399 | 0 | 0 | 1868 2001 BLOOD 98(11):373A-374A Uziel O; Shapira A; Radnay J; Lahav M; Lishner M Thalidomide downregulates transcript levels of GC-rich promoter genes in multiple myeloma. | 0 | 0 |
| 2400 | 0 | 3 | 173 1962 PRESSE MEDICALE 70(41):1899-& VAILLE C EN MARGE DE LAFFAIRE DU THALIDOMIDE - QUELQUES ASPECTS PSYCHOLOGIQUES | 0 | 1 |
Page 8: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22